查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596418

短肠症候群市场：依药物类别、通路划分 - 全球预测 2025-2030 年

Short Bowel Syndrome Market by Drug Class (GLP-2, Glutamine, Growth Hormone), Distribution Channel (Hospital Pharmacies, Online Sales, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年短肠症候群市场价值为81823万美元，预计到2024年将达到96642万美元，复合年增长率为19.14%，到2030年预计将达到278872万美元。

短肠症候群（SBS）是一种罕见且严重的疾病，其特征是小肠功能障碍，导致营养吸收不足。 SBS 的治疗范围包括营养支持、药物治疗和手术，强调需要有效的解决方案来改善患者的生活品质。 SBS 治疗用途包括肠外营养、经肠营养以及使用替度鲁肽等药物来增强吸收。最终用途范围包括医院、诊所和家庭护理环境，每种用途对市场需求的贡献不同。随着全球医疗格局的发展，SBS 市场的关键成长要素包括医学营养疗法的进步和对罕见疾病认知的提高。增强肠道适应的创新治疗方法的开发带来了潜在的商机，主要是在医疗保健系统发达的新兴经济体。由于医疗基础设施的改善和政府的倡议，新兴市场也充满希望。然而，高处理成本、严格的法律规范和 SBS 的复杂性是主要限制。需要个人化的患者管理计划和有限的可用病因治疗等挑战进一步使市场成长变得复杂。确定有前景的技术创新领域并开发专注于加强残余肠道功能的新疗法仍然很重要。生物技术公司和医疗机构之间的合作可以推进肠道微生物组操纵和生技药品开发的研究。此外，市场以病人为中心的性质与医学研究的进步密切相关，需要病人权益团体和专业组织持续参与，以解决未满足的需求。透过投资研发并采取以患者为中心的方法，公司可以透过客製化治疗、增强交付系统以及与目前的患者管理通讯协定保持一致而受益。这样的策略方向不仅可以开拓现有的商业机会，还可以有效地将公司定位在不断发展的 SBS 处理领域。

主要市场统计
基准年[2023] 81823万美元
预测年份 [2024] 9.6642亿美元
预测年份 [2030] 27.8872亿美元
复合年增长率（%） 19.14%

市场动态：揭示快速发展的短肠症候群市场的关键市场洞察

供需的动态交互作用正在改变短肠症候群市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 提高对短肠症候群的认识和认识计划
    • 加大力度开发有效的治疗方法
  • 市场限制因素
    • 缺乏核准的治疗方法和与药物相关的不良併发症
  • 市场机会
    • 短肠症候群治疗方法的开发尚处于早期阶段
    • 私人公司推动罕见疾病短肠症候群新药开发
  • 市场问题
    • 初步诊断的限制和高级选项的可用性

波特五力：驾驭短肠症候群市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解短肠症候群市场的外部影响

外部宏观环境因素在塑造短肠症候群市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解短肠症候群市场的竞争格局

对短肠症候群市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：短肠症候群市场供应商的绩效评估

FPNV定位矩阵是评估短肠症候群市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製短肠症候群市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对短肠症候群市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高短肠症候群和意识计画的接受度
      • 加强努力引入有效的治疗方法
    • 抑制因素
      • 缺乏核准的治疗方案和药物併发症
    • 机会
      • 短肠症候群药物开发尚处于早期阶段
      • 官民合作关係鼓励製药公司开发治疗短肠症候群的新孤儿药
    • 任务
      • 初步诊断的限制和高级选项的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章短肠症候群市场：依药物类别

  • 介绍
  • GLP-2
  • 麸酰胺酸
  • 生长激素

第七章短肠症候群市场：依分销管道

  • 介绍
  • 医院药房
  • 网上销售
  • 零售药房

第八章北美和南美短肠症候群市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太短肠症候群市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲短肠症候群市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc.
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Merck KGaA
  • Nestle SA
  • Novartis International AG
  • OPKO Health, Inc.
  • Oxthera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio and Company, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VectivBio AG
  • Viatris Inc.
  • Zealand Pharma A/S
Product Code: MRR-0309FBC51139

The Short Bowel Syndrome Market was valued at USD 818.23 million in 2023, expected to reach USD 966.42 million in 2024, and is projected to grow at a CAGR of 19.14%, to USD 2,788.72 million by 2030.

Short Bowel Syndrome (SBS) is a rare, serious condition characterized by the inability to adequately absorb nutrients due to insufficient functional small intestine. The scope of SBS treatment spans nutritional support, medications, and surgery, highlighting the necessity for efficient solutions in improving patient quality of life. Applications of SBS treatment encompass the use of parenteral nutrition, enteral nutrition, and drugs like teduglutide to enhance absorption. The end-use scope covers hospitals, clinics, and homecare settings, each contributing differently to the market demand. As the global healthcare landscape evolves, key growth factors in the SBS market include advancements in medical nutrition therapy and increasing awareness about rare diseases. The development of innovative therapies that enhance intestinal adaptation offers potential opportunities, predominantly in developed economies with robust healthcare systems. Emerging markets also present prospects due to improving healthcare infrastructure and government initiatives. Nonetheless, high treatment costs, stringent regulatory frameworks, and the complex nature of SBS act as significant limitations. Challenges such as the need for personalized patient management plans and limited available etiological therapies further complicate market growth. Identifying promising areas of innovation, the development of novel therapeutics focusing on enhancing residual bowel function remains critical. Collaboration between biotech firms and healthcare institutions can drive research into gut microbiome manipulation and biologics development. Moreover, the market's nature, being patient-centric and closely linked with advancements in medical research, necessitates continual engagement with patient advocacy groups and professional bodies to address unmet needs. Businesses can benefit by investing in R&D and adopting patient-centric approaches to tailor treatments, enhance delivery systems, and align with current patient management protocols. This strategic direction will not only tap into existing opportunities but also position businesses effectively in the evolving SBS treatment landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 818.23 million
Estimated Year [2024] USD 966.42 million
Forecast Year [2030] USD 2,788.72 million
CAGR (%) 19.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Short Bowel Syndrome Market

The Short Bowel Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Prevalence of Short Bowel Syndrome and Awareness Programs
    • Rising Efforts in the Launch of Effective Treatments
  • Market Restraints
    • Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
  • Market Opportunities
    • Development of Short Bowel Syndrome Drugs is at a Nascent Stage
    • Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
  • Market Challenges
    • Limited Initial Diagnostic and Availability of Advanced Option

Porter's Five Forces: A Strategic Tool for Navigating the Short Bowel Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Short Bowel Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Short Bowel Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Short Bowel Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Short Bowel Syndrome Market

A detailed market share analysis in the Short Bowel Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Short Bowel Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Short Bowel Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Short Bowel Syndrome Market

A strategic analysis of the Short Bowel Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Short Bowel Syndrome Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc., AstraZeneca PLC, Emmaus Life Sciences, Inc., Merck KGaA, Nestle S.A., Novartis International AG, OPKO Health, Inc., Oxthera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio and Company, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., VectivBio AG, Viatris Inc., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across GLP-2, Glutamine, and Growth Hormone.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Prevalence of Short Bowel Syndrome and Awareness Programs
      • 5.1.1.2. Rising Efforts in the Launch of Effective Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of Short Bowel Syndrome Drugs is at a Nascent Stage
      • 5.1.3.2. Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Initial Diagnostic and Availability of Advanced Option
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Short Bowel Syndrome Market, by Drug Class

  • 6.1. Introduction
  • 6.2. GLP-2
  • 6.3. Glutamine
  • 6.4. Growth Hormone

7. Short Bowel Syndrome Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Sales
  • 7.4. Retail Pharmacies

8. Americas Short Bowel Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Short Bowel Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Short Bowel Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 9 Meters Biopharma, Inc.
  • 2. Adocia SAS
  • 3. Ardelyx Inc.
  • 4. AstraZeneca PLC
  • 5. Emmaus Life Sciences, Inc.
  • 6. Merck KGaA
  • 7. Nestle S.A.
  • 8. Novartis International AG
  • 9. OPKO Health, Inc.
  • 10. Oxthera AB
  • 11. Pfizer Inc.
  • 12. PhaseBio Pharmaceuticals Inc.
  • 13. Sancilio and Company, Inc.
  • 14. Swedish Orphan Biovitrum AB
  • 15. Takeda Pharmaceutical Company Limited
  • 16. Teva Pharmaceutical Industries Ltd.
  • 17. VectivBio AG
  • 18. Viatris Inc.
  • 19. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. SHORT BOWEL SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SHORT BOWEL SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023